{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:14:45Z","timestamp":1740107685802,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Pharma Portugal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10067-020-05209-x","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T11:02:30Z","timestamp":1591959750000},"page":"33-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7217-0469","authenticated-orcid":false,"given":"Santiago","family":"Rodrigues-Manica","sequence":"first","affiliation":[]},{"given":"Joana","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Cruz-Machado","sequence":"additional","affiliation":[]},{"given":"Constan\u00e7a","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Elsa","family":"Vieira-Sousa","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Tavares-Costa","sequence":"additional","affiliation":[]},{"given":"Fernando M.","family":"Pimentel-Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"5209_CR1","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"5209_CR2","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"5209_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"LC Doward","year":"2003","unstructured":"Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20\u201326","journal-title":"Ann Rheum Dis"},{"key":"5209_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990) EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"issue":"Suppl 11","key":"5209_CR5","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1002\/acr.20633","volume":"63","author":"K Tang","year":"2011","unstructured":"Tang K, Beaton DE, Boonen A, Gignac MA, Bombardier C (2011) Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity And Activity Impairment Questionnaire (WPAI). Arthritis Care Res (Hoboken) 63(Suppl 11):S337\u2013S349","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5209_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bmj.306.6890.1437","volume":"306","author":"C Jenkinson","year":"1993","unstructured":"Jenkinson C, Coulter A, Wright L (1993) Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 306:1437\u20131440","journal-title":"BMJ."},{"key":"5209_CR7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","volume":"77","author":"U Kiltz","year":"2018","unstructured":"Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, Wei JC, Chiowchanwisawakit P, Dougados M, Duruoz MT, Elzorkany BK, Gaydukova I, Gensler LS, Gilio M, Grazio S, Gu J, Inman RD, Kim TJ, Navarro-Compan V, Marzo-Ortega H, Ozgocmen S, Pimentel Dos Santos F, Schirmer M, Stebbings S, Van den Bosch FE, van Tubergen A, Braun J (2018) Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis 77:1311\u20131317","journal-title":"Ann Rheum Dis"},{"key":"5209_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag 13:63\u201374","journal-title":"J Pain Symptom Manag"},{"key":"5209_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47\u201353","journal-title":"Ann Rheum Dis"},{"key":"5209_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Geher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compan V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978\u2013991","journal-title":"Ann Rheum Dis"},{"doi-asserted-by":"crossref","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, G\u00e9her P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Comp\u00e0n V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis","key":"5209_CR11","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"5209_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/ard.59.6.428","volume":"59","author":"F Van den Bosch","year":"2000","unstructured":"Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59:428\u2013433","journal-title":"Ann Rheum Dis"},{"key":"5209_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14712598.2018.1468884","volume":"18","author":"A Jones","year":"2018","unstructured":"Jones A, Ciurtin C, Ismajli M, Leandro M, Sengupta R, Machado PM (2018) Biologics for treating axial spondyloarthritis. Expert Opin Biol Ther 18:641\u2013652","journal-title":"Expert Opin Biol Ther"},{"key":"5209_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77:3\u201317","journal-title":"Ann Rheum Dis"},{"key":"5209_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1471-2474-15-333","volume":"15","author":"I Nota","year":"2014","unstructured":"Nota I, Drossaert CH, Taal E, Vonkeman HE, van de Laar MA (2014) Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey. BMC Musculoskelet Disord 15:333","journal-title":"BMC Musculoskelet Disord"},{"key":"5209_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","volume":"23","author":"V Strand","year":"2017","unstructured":"Strand V, Singh JA (2017) Patient burden of axial spondyloarthritis. J Clin Rheumatol 23:383\u2013391","journal-title":"J Clin Rheumatol"},{"key":"5209_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10:407\u2013415","journal-title":"Control Clin Trials"},{"key":"5209_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-015-0658-6","volume":"17","author":"SK Rai","year":"2015","unstructured":"Rai SK, Yazdany J, Fortin PR, Avina-Zubieta JA (2015) Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res Ther 17:143","journal-title":"Arthritis Res Ther"},{"key":"5209_CR19","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL, Cheng-Chung Wei J, Geusens P, Readie A, Richards HB, Martin R, Porter B (2016) Effect of Secukinumab on patient-reported outcomes in patients with active Ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol. 68:2901\u20132910","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 11","key":"5209_CR20","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling J (2011) Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) 63(Suppl 11):S47\u2013S58","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5209_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol group. Ann Med 33:337\u2013343","journal-title":"Ann Med"},{"key":"5209_CR22","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J (2005) Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32:811\u2013819","journal-title":"J Rheumatol"},{"unstructured":"(2019) Current version of RoB 2. https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/current-version-of-rob-2","key":"5209_CR23"},{"key":"5209_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Thabut G, Leblanc V, Logeart I (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70:799\u2013804","journal-title":"Ann Rheum Dis"},{"key":"5209_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3899\/jrheum.091042","volume":"37","author":"RD Inman","year":"2010","unstructured":"Inman RD, Maksymowych WP, Group CS (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37:1203\u20131210","journal-title":"J Rheumatol"},{"key":"5209_CR26","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58:3402\u20133412","journal-title":"Arthritis Rheum"},{"key":"5209_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3899\/jrheum.170487","volume":"45","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2018) Safety and efficacy of Golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol 45:341\u2013348","journal-title":"J Rheumatol"},{"doi-asserted-by":"crossref","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB, Group MS (2016) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis","key":"5209_CR28","DOI":"10.1136\/annrheumdis-2016-210023"},{"key":"5209_CR29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1756-185X.2012.01734.x","volume":"15","author":"Z Hu","year":"2012","unstructured":"Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, Wei Q, Zhang YL, Li T, Jin O, Huang J, Pan Y, Wu Y, Deng X, Gu J (2012) Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. Int J Rheum Dis 15:358\u2013365","journal-title":"Int J Rheum Dis"},{"key":"5209_CR30","first-page":"2030","volume":"35","author":"WP Maksymowych","year":"2008","unstructured":"Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, Wong RL, Inman RD, Group MS (2008) Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 35:2030\u20132037","journal-title":"J Rheumatol"},{"key":"5209_CR31","doi-asserted-by":"publisher","first-page":"R124","DOI":"10.1186\/ar2790","volume":"11","author":"DM van der Heijde","year":"2009","unstructured":"van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, Thompson C, Sieper J, Group AS (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther. 11:R124","journal-title":"Arthritis Res Ther."},{"key":"5209_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"5209_CR33","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, Berd Y, Bergman G, Curtis S, Tzontcheva A, Huyck S, Weng HH (2015) A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 67:2702\u20132712","journal-title":"Arthritis Rheumatol."},{"key":"5209_CR34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72:815\u2013822","journal-title":"Ann Rheum Dis"},{"key":"5209_CR35","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, Braun J, Sieper J (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58:1981\u20131991","journal-title":"Arthritis Rheum"},{"key":"5209_CR36","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66:2091\u20132102","journal-title":"Arthritis Rheumatol"},{"key":"5209_CR37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/acr.22594","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, Landewe R (2015) Impact of Certolizumab Pegol on patient-reported outcomes in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 67:1475\u20131480","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"5209_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s13075-014-0481-5","volume":"16","author":"M Dougados","year":"2014","unstructured":"Dougados M, Wood E, Combe B, Schaeverbeke T, Miceli-Richard C, Berenbaum F, Koppiker N, Dubanchet A, Logeart I (2014) Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther. 16:481","journal-title":"Arthritis Res Ther."},{"key":"5209_CR39","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P (2009) Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60:946\u2013954","journal-title":"Arthritis Rheum"},{"key":"5209_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3899\/jrheum.131003","volume":"41","author":"D van der Heijde","year":"2014","unstructured":"van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C, investigators G-R (2014) The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol 41:1095\u20131103","journal-title":"J Rheumatol"},{"key":"5209_CR41","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3899\/jrheum.141313","volume":"42","author":"M Dougados","year":"2015","unstructured":"Dougados M, Tsai WC, Saaibi DL, Bonin R, Bukowski J, Pedersen R, Vlahos B, Kotak S (2015) Evaluation of health outcomes with Etanercept treatment in patients with early nonradiographic axial Spondyloarthritis. J Rheumatol 42:1835\u20131841","journal-title":"J Rheumatol"},{"key":"5209_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 73:39\u201347","journal-title":"Ann Rheum Dis"},{"key":"5209_CR43","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS (2015) Secukinumab, an interleukin-17A inhibitor, in Ankylosing spondylitis. N Engl J Med 373:2534\u20132548","journal-title":"N Engl J Med"},{"key":"5209_CR44","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/acr.23233","volume":"69","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B, Group MS (2017) Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res (Hoboken) 69:1020\u20131029","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5209_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB (2017) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis 76:571\u2013592","journal-title":"Ann Rheum Dis"},{"key":"5209_CR46","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/acr.23276","volume":"69","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Lenaerts J, van den Bosch F, Wei JC, Pedersen R, Bonin R, Jones H, Marshall L, Logeart I, Vlahos B, Bukowski JF, Maksymowych WP (2017) Effects of long-term Etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken) 69:1590\u20131598","journal-title":"Arthritis Care Res (Hoboken)"},{"unstructured":"Higgins JP, Savovic J, Page MJ, Sterne JA, on behalf of the ROB2 Development Group (2019) Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). https:\/\/drive.google.com\/file\/d\/1xBzD1BeRrXH2DHg58fnTNKinTkX5SLEt\/view","key":"5209_CR47"},{"key":"5209_CR48","doi-asserted-by":"publisher","first-page":"e000499","DOI":"10.1136\/rmdopen-2017-000499","volume":"3","author":"E Nikiphorou","year":"2017","unstructured":"Nikiphorou E, Alunno A, Carmona L, Kouloumas M, Bijlsma J, Cutolo M (2017) Patient-physician collaboration in rheumatology: a necessity. RMD Open 3:e000499","journal-title":"RMD Open"},{"issue":"Suppl 3","key":"5209_CR49","first-page":"iii40","volume":"66","author":"TK Kvien","year":"2007","unstructured":"Kvien TK, Heiberg T, Hagen KB (2007) Minimal clinically important improvement\/difference (MCII\/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? Ann Rheum Dis 66(Suppl 3):iii40\u2013iii41","journal-title":"Ann Rheum Dis"},{"key":"5209_CR50","doi-asserted-by":"publisher","first-page":"b1147","DOI":"10.1136\/bmj.b1147","volume":"338","author":"F Song","year":"2009","unstructured":"Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 338:b1147","journal-title":"BMJ."},{"key":"5209_CR51","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.10397","volume":"47","author":"A Van Tubergen","year":"2002","unstructured":"Van Tubergen A, Debats I, Ryser L, Londono J, Burgos-Vargas R, Cardiel MH, Landewe R, Stucki G, Van Der Heijde D (2002) Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum 47:242\u2013248","journal-title":"Arthritis Rheum"},{"key":"5209_CR52","doi-asserted-by":"publisher","first-page":"e027354","DOI":"10.1136\/bmjopen-2018-027354","volume":"9","author":"S Bele","year":"2019","unstructured":"Bele S, Mohamed B, Chugh A, Haverman L, Santana MJ (2019) Impact of using patient-reported outcome measures in routine clinical care of paediatric patients with chronic conditions: a systematic review protocol. BMJ Open 9:e027354","journal-title":"BMJ Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05209-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05209-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05209-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T15:18:33Z","timestamp":1650208713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05209-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5209"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05209-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors except CC and JD declare collaborating and receiving fees from Novartis and other pharmaceutical companies either through participation in advisory board or consultancy, congress symposia, clinical trial conduct, investigator-initiated trials or grants. CC has no conflicts of interest. JD is an employee of Novartis Pharma Portugal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}